The Biovica board has appointed Theis Kipling as the new Chief Executive Officer. He will assume the position no later than September 2026.
Theis Kipling brings extensive international experience from leading global commercial organizations in the life sciences and diagnostics sectors. He has a strong track record of driving global sales growth and building successful commercial organizations. Most recently, he served as Chief Commercial Officer at Devyser Diagnostics and previously as Chief Commercial Officer at Atlas Antibodies.
” I have followed Biovica for many years. I am excited to join the team and contribute to helping oncologists monitor cancer progression. Biovica, with its assay, DiviTum® TKa, is a pioneer in the field, and I look forward to working alongside the great team at Biovica and continuing to develop and commercialize world-class products. I want to thank the board for the trust in me as we work towards successful high growth,” says Theis Kipling.
"The Board of Biovica and I are very pleased that Theis has agreed to lead Biovica into its next chapter. Over the past years, he has successfully driven global sales growth within the diagnostics industry and brings valuable leadership experience and commercial expertise to Biovica," says the company's chair, Fredrik Alpsten.
As previously announced, Anders Rylander, Biovica’s CEO for the last 15 years, announced earlier this year that he will step down as CEO in 2026. In a comment, Anders Rylander says:
“Theis Kipling brings highly relevant experience and is an excellent fit for Biovica. He has consistently driven commercial growth and built high-performing organizations. Under his leadership, I am confident Biovica will take the next step in its development and create significant long-term value for patients and shareholders.”
Further information contact:
Fredrik Alpsten, Chairman
+46 70 667 31 06